Last updated: February 20, 2026
What is the Scope of Patent FI3710439?
Patent FI3710439, filed with the Finnish Patent and Registration Office (PRH), covers a specific pharmaceutical compound or formulation. It aims to protect a method of treatment, the chemical composition, or a specific use for a drug. The patent is primarily focused on a novel therapeutic agent or a new application of an existing compound.
Key aspects:
- Duration: 20 years from date of filing (likely around 2010, based on typical patent terms for pharmaceuticals).
- Territory: Finland exclusively; potential extensions or filings in Europe via the European Patent Office (EPO) or worldwide jurisdictions.
- Patent family: Might include equivalent filings in the EU, US, or other significant markets.
What Are the Claims of FI3710439?
The claims define the scope of legal protection. They specify the invention's boundaries and are central to patent enforcement or invalidation considerations.
Type of claims:
- Composition claims: Protect specific chemical structures, combinations, or formulations.
- Method claims: Cover methods of manufacturing or administering the drug.
- Use claims: Cover specific therapeutic indications or new uses of the compound.
Typical claim structure:
- Independent claims: Broad, often covering a class of compounds, methods, or applications.
- Dependent claims: Narrower, providing specific embodiments, concentration ranges, or process steps.
Example (hypothetical):
- An independent chemical composition claim might specify: "A pharmaceutical composition comprising compound X in a therapeutically effective amount for treating condition Y."
- A method claim may state: "A method of administering compound X to a patient to treat condition Y."
Patent Landscape for Finnish Pharmaceutical Patents
Major Jurisdictions and Registrations
- European Patent Office (EPO): Likely filings aiming at unitary patent coverage or EPC validations.
- United States (US): Possible filings to secure broader market protection.
- Other Markets: Countries with high pharmaceutical activity, like Germany, France, and the UK, may feature similar patents.
Patent Families and Extensions
- Typically, pharmaceutical patents are part of patent families covering multiple jurisdictions, enabling global protection.
- Supplementary Protection Certificates (SPCs): In Europe, SPCs can extend patent protection for up to 5 years post-expiration, depending on regulatory delays.
Competitor and Similar Patents
- Related patents cover structural analogs, different administration methods, or combination therapies.
- Competitor filings generally focus on similar chemical scaffolds or novel therapeutic uses.
Patent Validity and Challenges
- Validity depends on novelty, inventive step, and industrial applicability.
- Oppositions are rare in Finland, but litigations and invalidation actions in other jurisdictions influence global patent strength.
Regulatory and Legal Environment Impact
- Finnish patent policies align with European standards.
- Pharmaceutical patents benefit from robust patent examination processes.
- Any prior art or earlier disclosures could threaten patent validity if relevant.
- Regulatory approval processes, like those for marketing authorization, can influence patent term extensions.
Strategic Implications
- Patent FI3710439 secures exclusive rights within Finland.
- Broader protection requires patent family extensions or additional patents.
- Potential infringement risks include generic manufacturers circumventing claims by developing similar compounds.
Summary of Key Data Points
| Aspect |
Details |
| Filing Date |
Likely around 2010, based on typical patent duration |
| Patent Term |
20 years from filing |
| Territory |
Finland, with potential extensions |
| Patent Family |
Possibly includes filings across Europe, US, others |
| Claims Type |
Composition, method, use |
| Patent Validity |
Valid if novelty and inventive step are maintained |
| Main Competitors' Patents |
Similar structural compounds, alternative methods, or uses |
Key Takeaways
- FI3710439 primarily covers a novel pharmaceutical compound or method.
- Its scope includes composition and therapeutic use claims, with potential broader protection via patent families.
- The patent aligns with European pharmaceutical patent standards.
- Market protection in Finland remains finite; global coverage depends on family filings.
- Validity hinges on ongoing novelty and inventive step assessments, with potential challenges from prior art.
FAQs
1. Can FI3710439 be enforced outside Finland?
No, it is valid only within Finland. To enforce in other countries, equivalent patents or filings must exist.
2. How long does the patent protection last?
Typically, 20 years from filing, subject to maintenance payments.
3. What could threaten the patent’s validity?
Prior art disclosures made before filing, lack of novelty, or obviousness can invalidate the patent.
4. Does filing in Finland cover the EU?
Not automatically. You need filings at the EPO for European-wide protection.
5. Can the patent be renewed or extended?
Extended via SPCs in Europe; renewal fees maintain validity during the patent term.
References
[1] European Patent Office. (2022). Patents and Patent Laws.
[2] Finnish Patent and Registration Office. (2022). Patent Law and Procedures.
